T1	CHEM 190 201	metotrexato
#1	AnnotatorNotes T1	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T2	PROC 77 88	monoterapia
#2	AnnotatorNotes T2	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T3	PROC 108 119	monoterapia
#3	AnnotatorNotes T3	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T4	DISO 135 154	artritis reumatoide
#4	AnnotatorNotes T4	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T5	DISO 156 158	AR
#5	AnnotatorNotes T5	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T6	PROC 245 289	Estudio de fase 3, aleatorizado, doble ciego
T7	PROC 327 338	monoterapia
#6	AnnotatorNotes T7	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T8	CHEM 348 359	metotrexato
#7	AnnotatorNotes T8	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T9	CHEM 361 364	MTX
#8	AnnotatorNotes T9	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T10	PROC 369 380	monoterapia
#9	AnnotatorNotes T10	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T11	CHEM 420 423	MTX
#10	AnnotatorNotes T11	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T12	DISO 428 447	artritis reumatoide
#11	AnnotatorNotes T12	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T13	DISO 495 514	Artritis Reumatoide
#12	AnnotatorNotes T13	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T14	DISO 516 518	AR
#13	AnnotatorNotes T14	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T15	DISO 544 563	Artritis Reumatoide
#14	AnnotatorNotes T15	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T16	DISO 565 567	AR
#15	AnnotatorNotes T16	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T17	PROC 685 696	Diagnóstico
#16	AnnotatorNotes T17	C0011900; Diagnosis; Diagnostic Procedure
T18	DISO 700 702	AR
#17	AnnotatorNotes T18	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T19	CHEM 739 742	MTX
#18	AnnotatorNotes T19	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T20	CHEM 820 823	MTX
#19	AnnotatorNotes T20	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T21	CHEM 878 881	MTX
#20	AnnotatorNotes T21	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T22	CHEM 934 941	fármaco
#21	AnnotatorNotes T22	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T23	PROC 727 734	tratado
#22	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	CHEM 1032 1035	MTX
#23	AnnotatorNotes T24	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T25	PROC 986 994	tratados
#24	AnnotatorNotes T25	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T26	DISO 1124 1134	enfermedad
#25	AnnotatorNotes T26	C0012634; Disease; Disease or Syndrome
T27	DISO 1151 1176	articulaciones inflamadas
#26	AnnotatorNotes T27	C0003864; Arthritis; Disease or Syndrome
T28	DISO 1203 1227	articulaciones dolorosas
#27	AnnotatorNotes T28	C0003862; Arthralgia; Sign or Symptom
T29	DISO 1292 1307	erosiones óseas
T30	PROC 1314 1325	radiografía
#28	AnnotatorNotes T30	C1306645; Plain x-ray; Diagnostic Procedure | C1962945; Radiographic imaging procedure; Diagnostic Procedure
T31	DISO 1362 1374	erosión ósea
T32	CHEM 1646 1657	baricitinib
#29	AnnotatorNotes T32	C4044947; baricitinib; Organic Chemical · Pharmacologic Substance
T33	DISO 1556 1568	Intolerancia
#30	AnnotatorNotes T33	C0277585; Intolerance to drug; Pathologic Function
T34	CHEM 1572 1575	MTX
#31	AnnotatorNotes T34	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T35	CHEM 1610 1626	inhibidor de JAK
T36	CHEM 1633 1644	tofacitinib
#32	AnnotatorNotes T36	C2930696; tofacitinib; Organic Chemical · Pharmacologic Substance
T37	DISO 1746 1769	artropatía inflamatoria
T38	DISO 1785 1787	AR
#33	AnnotatorNotes T38	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T39	DISO 1821 1851	síndrome de Sjogren secundario
#34	AnnotatorNotes T39	C0151450; Secondary Sjögren's syndrome; Disease or Syndrome
T40	CHEM 93 104	metotrexato
#35	AnnotatorNotes T40	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T41	CHEM 66 73	ABT-494
#36	AnnotatorNotes T41	C4308782; ABT-494; Organic Chemical · Pharmacologic Substance
T42	CHEM 301 308	ABT-494
#37	AnnotatorNotes T42	C4308782; ABT-494; Organic Chemical · Pharmacologic Substance
T43	PROC 395 403	tratados
#38	AnnotatorNotes T43	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T44	CHEM 1011 1018	FARMEsc
#39	AnnotatorNotes T44	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance (?) [fármaco modificador de enfermedad sintético convencional, 'conventional synthetic disease-modifying antirheumatic drugs (DMARD)']
T45	PROC 800 816	administraciones
#40	AnnotatorNotes T45	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T46	PROC 915 941	administración del fármaco
#41	AnnotatorNotes T46	C3469597; Administration of medication; Therapeutic or Preventive Procedure
T47	ANAT 1151 1165	articulaciones
#42	AnnotatorNotes T47	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T48	ANAT 1203 1217	articulaciones
#43	AnnotatorNotes T48	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T49	ANAT 1302 1307	óseas
#44	AnnotatorNotes T49	C0262950; Skeletal bone; Body Part, Organ, or Organ Component | C0391978; Bone Tissue; Tissue
T50	ANAT 1370 1374	ósea
#45	AnnotatorNotes T50	C0262950; Skeletal bone; Body Part, Organ, or Organ Component | C0391978; Bone Tissue; Tissue
T51	PROC 1416 1433	factor reumatoide
#46	AnnotatorNotes T51	C0201660; Rheumatoid Factor Measurement; Laboratory Procedure
T52	PROC 1445 1500	autoanticuerpos frente a péptidos cíclicos citrulinados
#47	AnnotatorNotes T52	C1318660; Anti-cyclic citrullinated peptide antibody level; Laboratory Procedure
T53	CHEM 1719 1725	FARMEb
T54	CHEM 1660 1670	filgotinib
#48	AnnotatorNotes T54	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T55	Date 12 16	2015
T56	LIVB 123 130	sujetos
#49	AnnotatorNotes T56	C0681850; Study Subject; Group
T57	Neg_cue 164 166	no
T58	Frequency 309 323	una vez al día
T59	LIVB 384 391	sujetos
#50	AnnotatorNotes T59	C0681850; Study Subject; Group
T60	Neg_cue 392 394	no
T61	LIVB 624 648	Adulto de cualquier sexo
#51	AnnotatorNotes T61	C0001675; Adult; Age Group + C0025266; Male population group; Population Group + C0043210; Woman; Population Group
T62	Age 653 680	18 años de edad en adelante
T63	Duration 711 720	≥ 3 meses
T64	Neg_cue 724 726	No
T65	Neg_cue 767 769	no
T66	Frequency 824 833	semanales
T67	Duration 885 894	4 semanas
T68	LIVB 978 985	sujetos
#52	AnnotatorNotes T68	C0681850; Study Subject; Group
T70	LIVB 1076 1082	sujeto
#53	AnnotatorNotes T70	C0681850; Study Subject; Group
T71	Neg_cue 1350 1361	ausencia de
T73	Dose 791 816	más de 3 administraciones
T74	Neg_cue 1019 1031	distintos de
T69	Neg_cue 1770 1781	distinta de
T72	PROC 1507 1526	visita de selección
#54	AnnotatorNotes T72	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T75	PROC 1255 1275	visitas de selección
#55	AnnotatorNotes T75	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T76	Quantifier_or_Qualifier 1278 1283	basal
A1	Status T1 History_of
A2	Assertion T1 Negated
A3	Status T43 History_of
A4	Status T11 History_of
A5	Population_data T61 Age
A6	Assertion T23 Negated
A7	Assertion T19 Negated
A8	Assertion T73 Negated
A9	Assertion T24 Negated
A10	Assertion T31 Negated
A11	Assertion T38 Negated
A12	Assertion T11 Negated
A13	Assertion T43 Negated
A14	Status T20 History_of
A15	Status T21 History_of
A16	Status T25 History_of
A17	Status T44 History_of
A18	Status T24 History_of
A19	Status T33 History_of
A20	Status T35 History_of
A21	Status T36 History_of
A22	Status T32 History_of
A23	Status T54 History_of
A24	Status T53 History_of
A25	Status T37 History_of
A26	Status T39 History_of
#57	AnnotatorNotes T6	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity
#58	AnnotatorNotes T37	C0003864; Arthritis; Disease or Syndrome
T77	PROC 1255 1262	visitas
#56	AnnotatorNotes T77	C1512346; Patient Visit; Health Care Activity
R1	Negation Arg1:T57 Arg2:T1	
R2	Negation Arg1:T60 Arg2:T43	
R3	Negation Arg1:T64 Arg2:T23	
R4	Negation Arg1:T64 Arg2:T19	
R5	Used_for Arg1:T19 Arg2:T23	
R6	Negation Arg1:T65 Arg2:T73	
R7	Has_Dose_or_Strength Arg1:T20 Arg2:T73	
R8	Negation Arg1:T74 Arg2:T24	
R9	Negation Arg1:T71 Arg2:T31	
R10	Negation Arg1:T69 Arg2:T38	
R11	Used_for Arg1:T41 Arg2:T2	
R12	Used_for Arg1:T40 Arg2:T3	
R13	Experiences Arg1:T56 Arg2:T41	
R14	Experiences Arg1:T56 Arg2:T40	
R15	Experiences Arg1:T56 Arg2:T4	
R16	Experiences Arg1:T56 Arg2:T5	
R17	Experiences Arg1:T56 Arg2:T1	
R18	Has_Frequency Arg1:T42 Arg2:T58	
R19	Used_for Arg1:T42 Arg2:T7	
R20	Used_for Arg1:T8 Arg2:T10	
R21	Used_for Arg1:T9 Arg2:T10	
R22	Experiences Arg1:T59 Arg2:T42	
R23	Experiences Arg1:T59 Arg2:T8	
R24	Experiences Arg1:T59 Arg2:T9	
R25	Experiences Arg1:T59 Arg2:T43	
R26	Used_for Arg1:T11 Arg2:T43	
R27	Experiences Arg1:T59 Arg2:T12	
T78	Quantifier_or_Qualifier 448 454	activa
#59	AnnotatorNotes T78	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R28	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T78	
T79	Quantifier_or_Qualifier 569 575	active
#60	AnnotatorNotes T79	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R29	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T79	
R30	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T79	
T80	Quantifier_or_Qualifier 1147 1150	≥ 6
R31	Location_of Arg1:T47 Arg2:T27	
R32	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T80	
R33	Experiences Arg1:T70 Arg2:T26	
R34	Experiences Arg1:T70 Arg2:T27	
R35	Experiences Arg1:T70 Arg2:T28	
T81	Quantifier_or_Qualifier 1199 1202	≥ 6
R36	Overlap Arg1:T27 Arg2:T28	
R37	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T81	
R38	Has_Quantifier_or_Qualifier Arg1:T77 Arg2:T76	
R45	Used_for Arg1:T44 Arg2:T25	
R46	Experiences Arg1:T68 Arg2:T25	
T82	CONC 1052 1069	periodo de lavado
#61	AnnotatorNotes T82	C1710661; Washout Period; Temporal Concept
R47	Has_Frequency Arg1:T20 Arg2:T66	
R48	Used_for Arg1:T20 Arg2:T45	
T83	CONC 857 874	periodo de lavado
#62	AnnotatorNotes T83	C1710661; Washout Period; Temporal Concept
R49	Has_Duration_or_Interval Arg1:T83 Arg2:T67	
R50	Before Arg1:T83 Arg2:T46	
R51	Used_for Arg1:T22 Arg2:T46	
R52	Has_Duration_or_Interval Arg1:T18 Arg2:T63	
R53	Has_Age Arg1:T61 Arg2:T62	
T84	Quantifier_or_Qualifier 579 595	moderada a grave
#63	AnnotatorNotes T84	C1299393; Moderate to severe; Qualitative Concept
R54	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T84	
R55	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T84	
T85	Quantifier_or_Qualifier 455 471	moderada a grave
#64	AnnotatorNotes T85	C1299393; Moderate to severe; Qualitative Concept
R56	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T85	
T86	Quantifier_or_Qualifier 1288 1291	≥ 1
R57	Location_of Arg1:T49 Arg2:T29	
#65	AnnotatorNotes T29	C0587240; Erosion of bone; Pathologic Function
#66	AnnotatorNotes T31	C0587240; Erosion of bone; Pathologic Function
R58	Has_Quantifier_or_Qualifier Arg1:T29 Arg2:T86	
T87	Result_or_Value 1399 1407	positivo
#67	AnnotatorNotes T87	C1446409; Positive; Finding
R60	Has_Result_or_Value Arg1:T51 Arg2:T87	
R62	Has_Result_or_Value Arg1:T52 Arg2:T87	
R64	Overlap Arg1:T52 Arg2:T72	
R65	Overlap Arg1:T51 Arg2:T72	
R67	Location_of Arg1:T50 Arg2:T31	
R68	Causes Arg1:T34 Arg2:T33	
#68	AnnotatorNotes T35	C3854325; Janus kinase inhibitor; Pharmacologic Substance
#69	AnnotatorNotes T53	C4055380; Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
#70	AnnotatorNotes T76	C1442488; Baseline; Quantitative Concept
R69	Experiences Arg1:T70 Arg2:T77	
R70	Experiences Arg1:T70 Arg2:T75	
A27	Assertion T82 Hypothetical
A28	Experiencer T68 Patient
A29	Experiencer T70 Patient
A30	Experiencer T56 Patient
A31	Experiencer T59 Patient
A32	Experiencer T61 Patient
